Substance Use Disorder Statistics in Rhode Island

Substance Use Disorder (SUD) represents a significant public health issue nationally and within Rhode Island. Across the United States, nearly 48.4 million people aged 12 or older meet the criteria for an SUD, affecting roughly one in six individuals^[4]. This includes 27.9 million with an alcohol use disorder and 28.2 million with a drug use disorder^[4]. In Rhode Island, approximately 8.2% of adults met the criteria for a past-year SUD in 2023^[8], a figure that has risen by 1.2 percentage points since 2020^[1]. This increase is considered statistically robust based on large sample sizes^[1].

The challenge of SUD is often compounded by co-occurring mental health conditions. In Rhode Island, 20.5% of adults experience any mental illness (AMI), and 4.8% live with a serious mental illness (SMI)^[3]. These psychiatric conditions are intricately tied to SUD, creating more complex treatment needs and highlighting the importance of integrated care^[10].

While the prevalence of SUD has risen, Rhode Island has made notable progress in reducing its most severe outcome: fatal overdoses. In 2024, the state recorded 329 accidental overdose deaths^[2]. This figure represents a significant 18.6% decrease from 2023 and contributes to a sustained two-year decline in mortality^[2]. The state also saw a 10% drop between 2022 and 2023^[2], reflecting the success of local intervention strategies^[3].

Despite this progress, the state's overdose death rate of roughly 18 per 100,000 residents remains a serious concern^[11], and some analyses suggest it remains 16-34% above national averages depending on the specific timeframe and metric used^[2]. For broader context, the state's suicide rate was 13.5 per 100,000 residents in 2021, slightly below the U.S. average^[12].

Rhode Island has made significant progress in reducing overdose fatalities, signaling the success of local intervention strategies^[3]. In 2024, the state recorded 329 accidental overdose deaths, an 18.6% decrease from the previous year^[2]. This continues a promising trend, contributing to a cumulative 25% drop in overdose deaths since 2022^[2]. This progress is a testament to coordinated harm reduction and treatment efforts across the state.

The substances driving SUD and overdose deaths in Rhode Island are varied and evolving. Opioids remain a primary driver of mortality, involved in 69% of overdose fatalities, with fentanyl specifically implicated in 57% of cases^[2]. However, recent data shows a shift, with cocaine-involved deaths surpassing those from fentanyl for the first time since 2013, often in cases involving multiple substances^[2].

Among young adults aged 18-25, substance use rates are notably high. Alcohol use prevalence is 72.1% and marijuana use is 30.7%, both significantly higher than national averages^[1]. Illicit drug use (excluding marijuana) in this age group is also higher at 9.9% versus 7.3% nationally^[1]. These rates are even more pronounced among young adults visiting emergency departments, where 43.3% report marijuana use and 14.2% report other illicit drug use^[1]. The primary route of administration for substances is smoking, reported by 90.1% of users, a factor with important implications for harm reduction strategies that have historically focused on injection drug use^[14][15].

Substance Use Disorder does not impact all communities equally. In Rhode Island, significant disparities exist across gender, age, and racial lines, influencing everything from prevalence rates to treatment access and mortality. Understanding these differences is crucial for developing equitable and effective public health responses.

Men in Rhode Island experience a higher prevalence of SUD (9.0%) compared to women (7.5%)^[3], constitute 55% of SUD patients^[17], and tragically account for approximately 70% of all overdose deaths^[2]. Age is also a critical factor; young adults show higher prevalence rates^[18], and initiating drug use at an early age can increase the risk of developing a full-blown SUD by up to six-fold^[19]. Meanwhile, tobacco and opioid analgesic use tends to peak among those aged 26-34^[1]. Perhaps most starkly, non-Hispanic Black Rhode Islanders continue to bear the highest burden of fatal overdose^[2].

The substance landscape in Rhode Island is complex and continually evolving. Opioids remain the primary driver of overdose deaths, with 69% of fatalities involving any opioid, and 57% involving fentanyl specifically^[2]. The widespread contamination of the drug supply with fentanyl poses a significant risk even to those who do not primarily use opioids; almost half of this group reports having witnessed an overdose^[21]. In a notable shift, 2024 marked the first time since 2013 that cocaine-involved overdoses surpassed those involving fentanyl, often in cases where multiple substances were present^[2].

While substance use prevalence is highest among young adults, the risk of a fatal overdose is most pronounced in middle-aged and older populations in Rhode Island. Data consistently shows that individuals aged 45 to 54 experience the highest fatal overdose rate in the state^[2]. This trend highlights the long-term, cumulative effects of chronic substance use and the need for targeted interventions for this demographic.

Notably, while overall overdose deaths have declined, the trend has not been uniform across all age brackets. Recent data indicates that fatal overdose rates decreased across all age groups except for those aged 55 to 64, suggesting this cohort may require specialized outreach and support services^[2].

Access to effective treatment is a cornerstone of addressing the SUD crisis. Nationally, the treatment gap is vast, with some estimates suggesting only one in five individuals with SUD receive any form of treatment^[4], while others report that 85% do not receive treatment^[7]. In Rhode Island, nearly 40% of those with SUD are not receiving care^[5]. While some reports indicate treatment rates as high as 62-65%^[5][8], this still means over a third of affected individuals do not receive evidence-based interventions^[8].

Rhode Island has a higher-than-average density of treatment facilities, with some reports citing 50 facilities per 100,000 population compared to a national average of 45^[2], and 15 licensed providers per 100,000 versus 10 nationally^[22]. However, significant barriers remain, including localized shortages, long wait times^[2], and an uneven distribution of providers between urban and rural areas^[3][23]. This is exacerbated by a broader shortage of mental health professionals, with a ratio of just one provider per 3,500 residents, leading to the state's designation as a Health Professional Shortage Area (HPSA)^[3][11].

Addressing the SUD crisis requires substantial financial investment. Rhode Island has committed significant resources, allocating approximately $20 million toward SUD treatment and prevention in 2023—a figure about 15% higher per capita than the national average^[2]. The state also ranks 12th in the U.S. for per capita mental health funding^[12]. Furthermore, funds from national opioid settlements have provided over $285 million to support treatment, prevention, and recovery services across the state^[2].

On the policy front, Rhode Island has taken proactive steps to improve access through insurance. Approximately 87% of the state's population has insurance covering mental health benefits, exceeding the national average of 80%^[12]. A landmark 2020 SUD Insurance Parity Act mandates that insurers, including Medicaid, cover SUD services with the same parity as other medical conditions^[24]. This legislation has had a meaningful impact on an estimated 25,000 lives by ensuring treatment is not improperly denied or limited^[24].

Despite having a higher-than-average density of treatment providers, significant barriers to care persist in Rhode Island. Nationally, only about one in five individuals with an SUD receive any form of treatment, meaning up to 85% go untreated^[4][7]. Recent federal data suggests Rhode Island's treatment utilization rate is around 35%, which is below the national average of 40%^[3]. Even for those who access care, more than one-third do not receive evidence-based interventions^[8]. Barriers include localized provider shortages, long wait times, and an uneven distribution of services between urban and rural areas^[3].

Rhode Island has made substantial financial and legislative commitments to combat the SUD crisis. The state passed a landmark SUD Insurance Parity Act in 2020, mandating that insurers treat SUD services with the same parity as other medical conditions, a move that has impacted an estimated 25,000 lives^[24]. In 2023, the state allocated approximately $20 million toward SUD treatment and prevention, which is about 15% higher per capita than the national average^[2]. Additionally, funds from the national opioid settlement have provided over $285 million to bolster treatment, prevention, and recovery services across the state^[2].

Understanding the national landscape provides context for Rhode Island's challenges. Of the 48.4 million Americans with a Substance Use Disorder, the condition breaks down into two major categories: alcohol use disorder and drug use disorder, with many individuals experiencing both. Nationally, 27.9 million people suffer from an alcohol use disorder^[4], while 28.2 million meet the criteria for a drug use disorder^[4]. Recent trends show a divergence in the prevalence of these conditions.

To build on recent successes, experts recommend several strategic shifts in Rhode Island's approach to SUD. One key recommendation is the integration of SUD management into the Chronic Care Model, which acknowledges the cyclical nature of relapse and remission and emphasizes long-term, continuous care rather than acute, episodic treatment^[13]. Harm reduction programs must also evolve to meet the needs of people who primarily smoke substances, as syringe-centric services may fail to reach many Black and Hispanic users^[15]. Finally, data showing a lack of decline in overdose deaths among the 55-64 age group indicates a clear need for targeted interventions for older adults.